• head_banner_01

OEM Supply Lithium Acetate - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We thinks what clients think, the urgency of urgency to act from the interests of a client position of theory, allowing for greater quality, lessen processing costs, price ranges are much more reasonable, won the new and outdated shoppers the support and affirmation for 7-Tmca, Iron 3 Acetate, Sodium(+)-10-Camphorsulfonate, We are glad that we are steadily growing with the active and long term support of our satisfied customers!
OEM Supply Lithium Acetate - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:

Product Detail

Name  Desmopressin
CAS number  16679-58-6
Molecular formula  C46H64N14O12S2
Molecular weight  1069.22
EINECS Number  240-726-7
Specific rotation  D25 +85.5 ± 2° (calculated for the free peptide)
Density  1.56±0.1 g/cm3(Predicted)
RTECS No.  YW9000000
Storage conditions  Store at 0°C
Solubility  H2O:soluble20mg/mL, clear, colorless
Acidity coefficient  (pKa) 9.90±0.15 (Predicted)

Synonyms

MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN

Indications

(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.

(2) Treatment of nocturnal enuresis (patients aged 5 years or older).

(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.

(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.

Treatment of diabetes insipidus

Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.


Product detail pictures:

OEM Supply Lithium Acetate - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures

OEM Supply Lithium Acetate - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures


Related Product Guide:

We stay with our company spirit of "Quality, Performance, Innovation and Integrity". We goal to create more value for our clients with our abundant resources, advanced machinery, experienced workers and superb solutions for OEM Supply Lithium Acetate - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: Sacramento, Manila, Finland, Whether selecting a current product from our catalog or seeking engineering assistance for your application, you can talk to our customer service center about your sourcing requirements. We can provided good quality with competitive price for you.
  • This manufacturer can keep improving and perfecting products and service, it is in line with the rules of market competition, a competitive company.
    5 Stars By Caroline from Ghana - 2017.04.18 16:45
    We are really happy to find such a manufacturer that ensuring product quality at the same time the price is very cheap.
    5 Stars By Sophia from Poland - 2018.10.09 19:07
    Write your message here and send it to us